Comparative Pharmacology
Head-to-head clinical analysis: BICILLIN L A versus DISPERMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICILLIN L A versus DISPERMOX.
BICILLIN L-A vs DISPERMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G benzathine is a slow-release formulation that provides prolonged tissue concentrations. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes, leading to cell lysis.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking.
1.2 million units intramuscularly as a single dose for treatment of streptococcal pharyngitis; for syphilis, 2.4 million units intramuscularly weekly for 1-3 weeks depending on stage.
Adults: 1 g (as amoxicillin 875 mg + clavulanate 125 mg) orally every 12 hours for 7-10 days.
None Documented
None Documented
Terminal half-life: 30-60 hours (prolonged due to slow absorption from IM depot; clinically allows single-dose regimen for syphilis)
Terminal elimination half-life 1.5 hours; prolonged in renal impairment.
Renal: 60-90% unchanged; biliary/fecal: minor (<10%)
Renal excretion 80% as unchanged drug, biliary/fecal 10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic